Dose-limiting bone marrow toxicities after Peptide Receptor Radionuclide Therapy are sexually dimorphic

#3368

Introduction: Peptide receptor radionuclide therapy (PRRT) can cause dose-limiting toxicities (DLTs) of the bone marrow, liver, and kidneys. It is yet unknown whether women and men are equally at risk for these DLTs.

Aim(s): To study the proportion of DLTs between women and men.

Materials and methods: Neuroendocrine tumor patients treated with 177Lu-DOTATATE between 2000 and 2015 in our phase II trial with available laboratory data were included. For all DLTs, the highest CTCAE (version 4.03) grades that occurred from the start of PRRT until 3 months after the last cycle were scored.

Conference:

Presenting Author: Minczeles N

Authors: Minczeles N, de Herder W, Konijnenberg M, Feelders R, Brabander T,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumor, haematological toxicity, sex,